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A B S T R A C T
Purpose: Resective surgical strategies are increasingly applied to treat medically-intractable epilepsy in
children as uncontrolled seizures are associated with poor cognitive, developmental and behavioral
outcomes. Innovative surgical strategies are, however, needed to improve outcomes and minimize the
morbidity of such procedures.
Method: The current article utilizes an axiological approach to explore and highlight ethical issues in the
use of high frequency oscillations (HFOs) to guide surgical resections in children with medically-
intractable epilepsy. We frame our discussion in the context of the broader challenges in the application
of surgical innovation to patient care.
Results: Despite a paucity of knowledge regarding their pathogenesis, limited evidence suggests the use
of HFOs as biomarkers of epileptogenicity in resective procedures can improve seizure outcome.
Clinicians must therefore weigh deﬁciencies in knowledge against the limited evidence supporting the
utility of HFOs and make ethical decisions for the treatment of individual patients. Important ethical
considerations for clinicians include the extent of deviation from established practice, the extent of
evidence required to establish clinical validity, and the impact of technique implementation on equitable
distribution of healthcare.
Conclusion: The use of HFO signatures to guide neocortical resections represents a novel approach for the
treatment of epilepsy. It is hoped that the issues discussed herein will contribute to and advance
meaningful dialog on the ethical application of this surgical innovation to the treatment of a very
vulnerable patient population.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Childhood epilepsy is a common neurological condition
associated with a considerable medical and psychosocial burden.
In up to one-third of children, medical therapy is ineffective at
decreasing seizure frequency. This sizeable group of children
represents an exquisitely vulnerable patient population, because
uncontrolled seizures have been linked to poor developmental,
cognitive and behavioral outcomes.1,2 Furthermore, a longer
duration of epilepsy is associated with a lesser likelihood of future
seizure-freedom, suggesting that early treatment is essential to
prevent chronic epilepsy, which can signiﬁcantly impair quality-* Corresponding author at: TorontoWestern Hospital, 399 Bathurst Ave, Toronto,
ON, Canada. Tel.: +1 416 603 5800x6499; fax: +1 416 603 5298.
E-mail address: mark.bernstein@uhn.ca (M. Bernstein).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.07.013of-life in children.3,4 It is not surprising therefore, that increasingly
aggressive surgical strategies have become more commonplace in
the treatment of medically-refractory childhood epilepsy. Indeed,
we have previously reviewed numerous ethical justiﬁcations for
surgical intervention, even in children with relatively modest
expected improvements or severe developmental delay.5
In contrast to adults, children often present with extensive
extra-temporal and multi-lobar epileptic foci. Therefore, the
accurate mapping and subsequent resection of the epileptogenic
zone – the minimum brain areas required for removal to achieve
seizure freedom – are of utmost importance. At present there is no
recognized gold standard for the determination of the epilepto-
genic zone. The use of ictal and interictal high frequency
oscillations (HFOs) as a biomarker of epileptogenicity to guide
neocortical resections has gained increasing popularity.6–9 HFOs,
which are acquired by applying frequency analysis to electroen-
cephalographic recordings from implanted subdural electrodes,vier Ltd. All rights reserved.
Table 1
Stratiﬁcation of innovative surgical procedures based on their need for regulation
(modiﬁed from Bernstein and Bampoe, 200422).
Level Description Example
A-1 New procedure (elective) Human implantation with
vagus nerve stimulators49
A-2 New procedure (urgent) Multiple subpial transections
for refractory status epilepticus50
B New procedure in RCT Anterior thalamic deep brain
stimulation for epilepsy51
C Modiﬁcation of a
technique of
an established
procedure
Reconstructing 3D magnetic
source imaging using
neuronavigation to facilitate
cortical resections52
D Modiﬁcation of other
feature of an
established procedure
Use of HFOs to guide surgical
resections (reported in
referenced retrospective series)
E New procedure to an
individual surgeon/
institution
Use of monopolar trains of ﬁve for
direct cortical stimulation
in epilepsy surgery at the
Hospital for Sick Children53
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bursting principal cells localized to a discrete neuronal cluster.10 It
has been shown in animal models that the presence of
electroencephalographic HFOs precedes clinical seizures following
an epileptogenic injury11 and that the number of electrodes
expressing HFOs is associated with higher seizure frequency.12
Furthermore, small retrospective series have demonstrated that
resection of cortical regions expressing HFOs is associated with
improved post-surgical outcomes.8,9,13,14 Our institution has
previously described the use of fast-ripple band power as a
marker of epileptogenicity to guide neocortical resections, using
multiple band frequency analysis.8,9
While a conﬂuence of low-level evidence suggests that HFOs
may be a useful marker to guide resective epilepsy surgery,
important unanswered questions temper the enthusiasm for their
broad application to patient care. Firstly, the physiological
mechanisms underlying the generation of epileptic HFOs are as-
of-yet unknown and furthermore, normal cortex in human and
animal models has been shown to exhibit oscillations in the HFO
range.15,16 Additionally, the fundamental neuronal mechanisms
that underlie the propagation, synchronization, coalescence and
expansion of HFOs leading to the ictus have yet to be elucidated.
Finally, long-term follow-up data are lacking, which poses a
signiﬁcant challenge given that recurrence of seizures may be
delayed by many years following surgical resection.17 The
challenge for clinicians is, therefore, to balance low-level popula-
tion-based evidence supporting the use of HFOs to guide surgical
resection with an incomplete understanding of the pathophysiol-
ogy of HFOs and ultimately make ethical decisions for individual
patients. This challenge is furthermore augmented by the invasive
and irreversible nature of resective surgery.
At present, there are no accepted guidelines or frameworks in
place to guide the surgeon in evaluating surgical innovations and
ethically applying them to patient care. The current article
presents germane ethical issues for clinicians regarding the use
of HFOs to guide surgical resection within the broader context of
challenges in applying surgical innovations to patient care. It is
hoped that the considerations presented herein will facilitate and
advance meaningful dialog on the utility of this emerging tool in
the armamentarium of epileptologists and neurosurgeons in the
management of drug-resistant epilepsy.
2. Methods
We applied an axiological approach to highlight ethical issues
in the use of HFOs to guide resective epilepsy surgery, whereby a
series of ethically-relevant questions is posed to underscore key
issues. This method is described in-depth by Hofmann18 and has
been effectively applied to the ethical analyses of other surgical
innovations, such as bariatric surgery.19 Axiological ethics is based
on the principle that judgments should be based on the value of an
object or process. Such determinations may encompass its
associated actions, motives and consequences. The approach is
deﬁned by a set of interrelated moral questions that may be
relevant in the assessment of health technology.18 These questions
are grouped into ﬁve broad categories, namely related to (a) moral
issues; (b) the stakeholders of the surgical innovation; (c) the
technology itself; (d) methodological choices; and (e) technology
assessment.
In the current axiological study, we concatenated multiple
categories into three overarching questions to highlight relevant
ethical considerations. The questions are neither exhaustive nor
exclusive and their objective is neither todevelop recommendations
nor to build a useable framework; rather, their purpose is to clearly
and methodologically highlight selected ethical considerations toadvance dialog on the ethical use of HFOs to guide surgical
resections.18
2.1. To what extent does the use of HFOs to guide resective epilepsy
surgery deviate from established practices?
Partially created in response to the unethical research practices
of the Tuskegee Syphilis Study (1932–1972), the Belmont report
outlines ethical criteria for the conduct of human research.
Therein, innovation is deﬁned as ‘‘practice that departs signiﬁ-
cantly from the standard or accepted’’.20 McKneally further
distinguishes between innovation and research by proposing that
in contrast to the latter, the former is characterized by evolving
techniques, outcome measures and patient selection.21 The extent
to which a novel surgical practice requires regulation and careful
oversight of its broad application to patient care is directly related
to the degree to which it deviates from established practices. The
senior author (M.B.) has previously proposed a classiﬁcation
system to stratify surgical (and speciﬁcally neurosurgical)
innovations based on their need for such regulation.22 In Table
1, we present a modiﬁed version of this classiﬁcation system with
examples of surgical innovations in epilepsy. In keeping with this
system, the inclusion of HFO data to guide resective epilepsy
procedures can be considered a modiﬁcation of the established
procedure of invasive monitoring and cortical resection.
Obtaining the information to perform frequency analysis does
not necessarily require any alteration to standard invasive
monitoring, however, these data can be used to alter the resection
strategy, according to the following four scenarios: (a) HFO analysis
may corroborate resection margins based on conventional localiza-
tion methods; (b) HFO analysis may suggest a more extensive
resection is required; (c) HFO analysis may suggest that a less
extensive resection may be sufﬁcient; or (d) the widespread
presence of HFOsmay indicate that a resective procedure is unlikely
to accomplish seizure-freedom and therefore invasive intracranial
electrodes should be removed without neocortical resection.
For scenario (a), since the use of HFOs does not alter the
proposed resection plan, there is essentially no deviation from
standard practice, but ethical conﬂicts may arise nonetheless. It
remains important in circumstances where innovative technology
is introduced to patient care to recognize the distinction between
innovations in technique and innovations in technology.22 While
the technique may be unaltered in this scenario, a novel
technology has been introduced. Recognition of this fact is
important, as patients may be exposed to harm if the technology
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deﬁning abnormal thresholds for resections.23 Furthermore, one
needs to be cognizant of circumstances when only slight and
seemingly-insigniﬁcant modiﬁcation are made based on the novel
technology, as these may have implications for patient care. For
example, invasive monitoring may need to remain in-place for a
longer period of time to collect adequate data for HFO analysis,
putting the patient at greater risk of infection. Indeed, a recent
survey of academic surgeons found that differentiating minor
surgical modiﬁcations from extensive alterations in technique is
challenging, particularly when changes are made incrementally or
on an as-need basis for individual patients.24
For scenarios (b), (c) and (d), where discordance arises between
the proposed resection andHFO proﬁles of the cortex, there is a risk
of exposing patients to harm by not sufﬁciently removing
epileptogenic areas, which can fail to achieve a satisfactory seizure
outcome or by applying an over-aggressive strategy, which can
result in iatrogenic neurological deﬁcits. Germane to their right to
autonomy, patients (and parents in the case of children) may
choose to sacriﬁce eloquent brain for a certain likelihood of
seizure-freedom.5 The acceptable risk-to-perceived-beneﬁt ratio,
which is in part dictated by the severity of the epilepsy syndrome
and the perceived likelihood of seizure-freedom is discussed in
informed consent discussions.
It is useful when addressing such ethical conﬂicts to consider
whether other technologies are subject to similar ethical
dilemmas. Indeed, the problem of extent of resection in the
context of limited evidence for a speciﬁc localization modality is a
pervasive challenge in epilepsy surgery. This is further augmented
by the lack of consensus for a standard of care. For instance, a
structural MRImay show a lesion, however, resection of this lesion
may be insufﬁcient to bestow seizure freedom. Alternatively, a PET
scan may demonstrate a large area of hypometabolism, but a
smaller resection may be adequate to achieve seizure freedom.
Therefore, it is pertinent that the concordance of numerous
localization modalities typically correlates with good outcomes.25
Informed consent discussion and pre-operative planning should,
therefore, focus on the multimodality use of these technologies.
While HFOs are a seemingly robust marker of epileptogenicity,
until more thorough research is conducted, it must be recognized
that at present, there is inadequate evidence to suggest that they
are less fallible than other localization tools and discordance with
other localization modalities should be discussed during the
consent process.
The impact of the novel innovation on patient counseling and
prognostication is also noteworthy. For example, if the clinician
knew that residual cortex expressed HFOs, he/she could counsel
the patient regarding risk of seizure recurrence accordingly. Before
this is accomplished, the validity of HFOs would need to be better
established and greater knowledge regarding their predictive
value would need to be ascertained. Clinicians should be aware,
however, that with the introduction of these surgical innovations
to patient care, the patient encounter itself, not only the surgical
procedure, would be affected.
2.2. What is the minimum sufﬁcient level of evidence required before
acceptance of HFOs as a bona ﬁde surgical adjunct?
Evidence-based medicine has become a major driving force in
clinical research and signiﬁcantly changed clinical practice over
the last several decades. Randomized controlled trials (RCTs)
speciﬁcally are the gold-standard for evaluation of a procedure’s
efﬁcacy. The importance of adequate evidence for ethical clinical
care, is highlighted by the troublesome history of ‘innovative’
treatments for epilepsy, which included amputation of affected
limbs, colectomy and purgation.26,27 Despite the importance ofevidence in guiding clinical practices, the majority of surgical
innovations do not undergo randomized clinical trials; therefore,
the standard of ‘adequate evidence’ is unclear.28,29 In fact, authors
have previously suggested that ‘‘one should not unnecessarily
obstruct surgical innovation by always insisting on orthodox and
rigid adherence to the tenets of the prospective randomized
double-blind controlled trial’’.30
It is highly unlikely that the use of HFOs to guide neocortical
resections will be subject to a formal RCT. For the conduct of such
trials, and to ethically randomize patients into treatment cohorts,
equipoise must be present between the two treatment arms under
consideration. It is uncommon in epilepsy surgery to have true
equipoise, as resections are tailored to the individual circum-
stances of the child. These include preoperative burden of disease,
willingness to accept varying degrees of risk incurred by iatrogenic
injury to eloquent cortex and considerable heterogeneity in
epileptic network size, extent and organization.5
A methodologically rigorous design may involve a two-stage
surgery, whereby a smaller cortical resection is ﬁrst attempt,
followed by amore extensive resection. The formermay be deﬁned
by traditional localization modalities (scenario b above) or by HFO
analysis (scenario c above). If the patient fails to achieve seizure-
freedom, a second stage surgery can be planned to remap the area.
There are, however, numerous concerns raised by such designs.
Firstly, from an ethical perspective, clinicians must question
whether to subject the patient to the risks of a two-stage
procedure. Furthermore, given the impediment of prolonged
uncontrolled seizures, it may be unethical to not perform the
most extensive safe resection upfront, particularly if all the
epileptogenic tissue is in non-eloquent cortex. Secondly, from an
epilepsy perspective, various challenges arise, including the
‘‘running down phenomenon’’, whereby seizures may remit after
a period of months to years following surgery.31,32 This is thought
to result following failure to resect the entire epileptogenic zone,
where the remaining regions are not sufﬁcient to indeﬁnitely
generate seizures autonomously. The running down phenomenon,
in combination with unpredictable post-operative epileptic
network reorganization would confound timing for a second stage
procedure, as well as the conclusions derived from such a study
design.
The best available evidence for the use of HFOs are small case
series, which are limited by factors such as patient selection bias, a
potential for lack of generalizability as these studies are typically
conducted by single operators at a speciﬁc centre (i.e. limited
external validity), as well as inadequate or variable follow-up.33 In
a recent position statement pertaining to the regulation of surgical
innovations, the Society of University Surgeons suggested that if
outcomes of an innovation have not been previously detailed, then
a review by a local surgical innovations committee must be
conducted, the innovation should be submitted to the national
innovations registry and additional informed consent is required of
the patient.34 Alternatively, it has been suggested that appropriate
progression to widespread adoption of a novel innovation includes
performing observational studies with some degree of standardi-
zation of the procedure and an attempt to involve multiple
surgeons at different centers.33
An additional challenge arises from obtaining informed consent
for future prospective studies of HFO-guided resections. In their
proposed ‘‘Surgical Innovation Ethics Paradigm’’, McKneally and
Daar propose that patients undergoing innovative procedures
must be told that they are free to choose standard care rather than
the experimental treatment.35 This poses an additional challenge
to research in this ﬁeld, as signiﬁcant heterogeneity exists in the
practice of pediatric epilepsy surgery.36 Discrepancies exist
between localization modalities, and procedures such as preva-
lence of surgery for non-lesional epilepsy cases. Furthermore, the
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for the treating physicians as both the healthcare provider and
clinical investigator, as these responsibilities may carry different
and competing obligations.37,38 The patients may demonstrate a
‘‘therapeutic misconception’’, when they mistake their involve-
ment in research as part of their care. This is particularly important
given that families of children with epilepsy are highly motivated
to seek novel treatments to mitigate the detrimental effect of
seizures.39 We have previously explored this topic in-depth in
other vulnerable patient groups, including those with brain
tumors.40
Finally, in light of obstacles encountered in obtaining high
quality epidemiological research, it is important to generate
theoretical evidence of the use of HFOs to guide neocortical
resections by attempting to understand their pathogenesis and
role within broader epileptic networks. Such theoretical under-
pinnings may serve to legitimize this surgical innovation and
provide more evidence to ethically justify its use in clinical
populations. For instance, it would be important to understand
why and how HFOs spread to distributed cortical areas during
seizures41 and how to differentiate normal from pathological HFO
signatures.
2.3. Does the implementation of HFO-guided resections affect the
distribution of healthcare?
We have previously published that inequity in access to
pediatric epilepsy surgery remains a pervasive problem that can
stem from variable referral practices and discrepancies in
diagnostic tools.42 For instance, centers utilizing a 1.5 T MR
scannermaymiss lesions that are conspicuous on a 3 T scanner and
therefore, the geographic location of a particular patientmay affect
their chances of seizure-freedom. Two ethical issues arise from the
use of HFOs with respect to the distribution of healthcare: (1) the
implementation of HFO-guided resections at speciﬁc centers may
further contribute to inequities in access to epilepsy surgery; and
(2) as novel innovations are almost always more expensive than
existing treatments, the use of HFOs may divert resources from
more established, and effective alternatives.23
With regards to the ﬁrst issue under consideration, it has been
clearly outlined that that societies, institutions and governments
have an ethical obligation to facilitate equitable access to health-
related resources.43 This obligation is, however, also balanced by a
responsibility to strive to improve current practices and surgical
innovations are one way to improve outcomes for children with
medically-intractable epilepsy. Furthermore, given the heteroge-
neity in practice of epilepsy surgery, the ethical challenge of
providing equitable care is not unique to the use of HFOs to guide
neocortical resections. Better guidelines are required to guide
resource allocation to pre-surgical evaluation of such patients.
A related ethical consideration concerns the questionable
generalizability of published outcome data in the hands of less
experienced centers and the related issue of the surgeon’s
professional autonomy to make the best decisions for his/her
patients based on their individual experience. It is indeed possible
that the widespread adoption of a novel surgical procedure may
result in worse outcomes in centres with less experience or patient
volume, thereby increasing the aforementioned regional dispa-
rities. The so-called ‘‘learning curve’’ is a well-described challenge
in applying surgical innovations to patient care.44 In recent years,
there has been an increased focus on the publication of surgeons’
performances, the so-called ‘‘surgeon’s report card’’,45,46 as
justiﬁed by numerous ethical arguments surrounding professional
obligations and patient rights. The extent to which regional
reporting of outcomes following application of surgical innova-
tions is required remains an area of ongoing debate.The second issue is more nuanced and pertains to optimism
bias, that is the tendency to overestimate the positive effects of an
innovation, thereby contributing both to difﬁculties in assessing
efﬁcacy and overzealous enthusiasm for widespread and prema-
ture applications to patient care.47 The risk, therefore, is that
frequency analysis software (which remains an expensive
alternative to visual detection of epileptogenic cortex on intracra-
nial EEG) may become adopted as a fad due to its perceived
novelty. The questions that would need to be answered before
centres divert funding to develop these techniques would not only
be whether HFOs analysis leads to improved outcomes, but also
how great of an effect is achieved as a result. A marginal outcome
beneﬁt may be off-set by the inaccessibility to the technology. This
may be analogous to ethical challenges in oncology, where the
prescription of expensive pharmaceuticals is debated if the
outcome beneﬁt is only marginally superior to less expensive
alternatives.48
3. Conclusions
Children with drug-resistant epilepsy represent a vulnerable
patient population because of the detrimental effects of uncon-
trolled seizures on development, cognition, and behavior.
Advances in the surgical treatment of intractable epilepsy have
contributed to the improvements in seizures outcomes. Innova-
tions in seizure-localization represent a step towards the
amelioration of the lives of affected children. Enthusiasm for
innovative localization tools, namely electroencephalographic
HFOs must however be tempered by evidence-based outcomes,
pragmatism and ethical principles. Using an axiological approach,
we explored three ethical questions pertaining to the extent to
which HFO analysis deviate from established procedures, the level
of evidence required prior to widespread adoption and the effects
of using these technique on healthcare distribution. It is hoped that
the discussion presented herein will contribute to and advance
meaningful dialog on this novel technique.
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